You are here

breast cancer

Spine devices, recalls and endovascular stents on FDA's fall meeting lineup

Medtech Dive

Thu, 09/9/21 - 11:03 am

endovascular stents

MacroGenics flips over an OS dud for cancer drug Margenza in surprising turnaround from earlier data

Endpoints

Tue, 09/7/21 - 10:48 pm

Roche pulls Tecentriq breast cancer nod after post-approval trial flop

Fierce Pharma

Sat, 08/28/21 - 09:04 pm

triple negative breast cancer

postmarketing studies

FDA issues warning on robot-assisted breast cancer surgery

Pharmaforum

Sun, 08/22/21 - 09:48 pm

robotic surgery

Two More Cancer Drug Candidates Hit the Fast Track

BioSpace

Mon, 08/16/21 - 12:16 pm

fast track status

Carrick Therapeutics

SeaGen builds cancer drug pipeline with China biotech deal

BioPharma Dive

Mon, 08/9/21 - 11:47 pm

AstraZeneca and Daiichi Sankyo continue to flesh out Enhertu plans, claiming win in earlier breast cancer line

Endpoints

Mon, 08/9/21 - 10:55 am

Merck rebounds to win a milestone immunotherapy approval in early breast cancer

BioPharma Dive

Tue, 07/27/21 - 04:39 pm

The search for a better Faslodex continues

EP Vantage

Mon, 07/26/21 - 10:12 pm

drug development

Pfizer funnels $1B into protein degrader Arvinas, with more in biobucks on the table

Fierce Biotech

Thu, 07/22/21 - 11:15 am

protein degradation

Bayer's drug that turns a cancer-protective pathway toxic eradicates breast tumors in mice

Fierce Biotech

Wed, 07/21/21 - 08:44 pm

Systems Oncology

Polyphor sharpens ax on staff, shutters failed breast cancer test

Fierce Biotech

Fri, 07/16/21 - 10:43 am

clinical trials

FDA 'may require' post-marketing studies to analyze long-term effects of breast cancer drugs

RAPS.org

Mon, 06/21/21 - 10:13 pm

post-marketing studies

Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test

Endpoints

Tue, 06/8/21 - 11:21 am

clinical trials

antibody-drug conjugate

AstraZeneca Redefining Cancer Care in Breast Cancer, Leukemia at ASCO

BioSpace

Mon, 06/7/21 - 08:41 pm

#ASCO21: Gilead's Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients

Endpoints

Fri, 06/4/21 - 11:00 am

Gilead Sciences

triple negative breast cancer

An AstraZeneca, Merck drug slows the return of genetic breast cancer. Will testing speed up?

BioPharma Dive

Thu, 06/3/21 - 11:11 pm

genetic breast cancer

Sanofi ASCO Preview: Addressing Unmet Needs in Breast Cancer

BioSpace

Thu, 06/3/21 - 11:08 pm

clinical trials

#ASCO21: Novartis keeps building out survival data for Kisqali, hoping to keep the pressure on Pfizer's Ibrance

Endpoints

Thu, 06/3/21 - 12:09 am

ASCO: Sanofi says early amcenestrant data could see it be 'endocrine backbone therapy' in breast cancer

Fierce Biotech

Wed, 05/19/21 - 11:24 pm

Pages